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Antimicrobial resistance is a major threat to global health, 
endangering the ability to prevent and manage many common 
infectious diseases.1,2 High rates of use and misuse of antibiot-
ics have contributed to selection pressures on drug-resistant 
strains of common pathogens, leading to a shift towards 
more expensive and broad-spectrum antibiotics.3 In 2015, 
the World Health Assembly adopted a Global Action Plan on 
Antimicrobial Resistance, calling for optimization of the use 
of antimicrobials.4 Key to optimization is to promote access 
to appropriate antibiotics while avoiding excess use.
The Access, Watch and Reserve (AWaRe) categorization is 
a tool introduced by the World Health Organization (WHO) 
to encourage antibiotic stewardship and to combat antimicro-
bial resistance.5 The categorization was first introduced in the 
2017 WHO essential medicines list, in which key antibiotics 
were classified into three categories – Access, Watch and Re-
serve – according to their therapeutic and resistance profile.6 
Access group antibiotics are defined as priority treatments 
recommended as first- and second-choice options for com-
mon infections that should be available and affordable in all 
countries. The Watch group contains broad-spectrum antibiot-
ics with a higher resistance potential that are recommended 
for a specific, limited number of indications. The Reserve 
group includes antibiotics for multidrug-resistant infections 
that should be treated as last-resort options in highly specific 
patients and settings. Recognizing the role of the AWaRe 
as a policy tool, the WHO essential medicines list expert 
committee updated the classification in 2019 to categorize 
additional antibiotics into the three groups and to add a new 
category: Not Recommended.7,8 To reduce the use of Watch 
and Reserve group antibiotics, the WHO Thirteenth General 
Programme of Work 2019–2023 has adopted the following 
target to be reached by 2023: at least 60% of national antibiotic 
consumption should be from the Access group.9,10 Adoption 
of this target at the national level should help to inform and 
galvanize action and can be used to monitor progress, allowing 
for comparison of antibiotic stewardship efforts.
Global antibiotic consumption and prescribing behav-
iours have been described in studies in different countries, with 
variations in study years, data sources, breadth of analysis and 
patient populations (for example, paediatrics, hospital setting 
or overall population).11–15 In relation to AWaRe, antibiotic 
consumption by children has been measured against the 2017 
AWaRe classification, with several countries falling short of 
the target of 60% use of Access group antibiotics.16,17 Similar 
findings have been observed in general population studies, 
including the WHO report on surveillance of antibiotic con-
sumption and a recent multi-country analysis, both using data 
up to 2015.15,18 We aimed to add to this body of work by using 
sales data to assess patterns of antibiotic sales according to the 
2019 AWaRe categories in eight high-income countries over 
the years 2013–2018. The objectives were to inform policy dis-
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Objective To compare antibiotic sales in eight high-income countries using the 2019 World Health Organization (WHO) Access, Watch and 
Reserve (AWaRe) classification and the target of 60% consumption of Access category antibiotics.
Methods We analysed data from a commercial database of sales of systemic antibiotics in France, Germany, Italy, Japan, Spain, Switzerland, 
United Kingdom of Great Britain and Northern Ireland, and United States of America over the years 2013–2018. We classified antibiotics 
according to the 2019 AWaRe categories: Access, Watch, Reserve and Not Recommended. We measured antibiotic sales per capita in standard 
units (SU) per capita and calculated Access group sales as a percentage of total antibiotic sales.
Findings In 2018, per capita antibiotic sales ranged from 7.4 SU (Switzerland) to 20.0 SU (France); median sales of Access group antibiotics 
were 10.9 SU per capita (range: 3.5–15.0). Per capita sales declined moderately over 2013–2018. The median percentage of Access group 
antibiotics was 68% (range: 22–77 %); the Access group proportion increased in most countries between 2013 and 2018. Five countries 
exceeded the 60% target; two countries narrowly missed it (> 55% in Germany and Italy). Sales of Access antibiotics in Japan were low 
(22%), driven by relatively high sales of oral cephalosporins and macrolides.
Conclusion We have identified changes to prescribing that could allow countries to achieve the WHO target. The 60% Access group target 
provides a framework to inform national antibiotic policies and could be complemented by absolute measures and more ambitious values 
in specific settings.
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cussions and to assess progress towards 
the WHO Access group target.
Methods
Study design
To obtain indication of antibiotic con-
sumption patterns, we used aggregate 
sales data as proxy. We analysed whole-
sale antibiotic sales data for 2013–2018 
from eight countries to determine 
patterns of sales with reference to the 
2019 WHO AWaRe classification.8,19 The 
countries included were: France, Ger-
many, Italy, Japan, Spain, Switzerland, 
United Kingdom of Great Britain and 
Northern Ireland, and United States of 
America (USA). We chose the countries 
and years of observation based on the 
availability of data. The included coun-
tries are representative of high-income 
countries with large pharmaceutical 
markets, in regions with varying antibi-
otic resistance profiles and health-care 
contexts.
Data sources
We used the IQVIA multinational in-
tegrated data analysis system database 
(IQVIA Inc., Durham, USA) to iden-
tify antibiotic sales. This commercial 
database tracks pharmaceutical sales 
by using national sales audits of manu-
facturers and wholesalers, through retail 
and non-retail channels.20,21 IQVIA 
standardizes the data to ensure they 
are nationally representative and to al-
low for comparability across markets. 
Table 1 shows the data sources and cov-
erage of the database for our sample. We 
extracted national quarterly sales data of 
all single and combination antimicrobial 
medicines. For our data extract IQVIA 
aggregated the data across hospital and 
community sectors and captured sales 
by generic and nongeneric manufactur-
ers; the data do not distinguish between 
indication or patient characteristics. 
IQVIA data are routinely used to under-
stand sales volumes of pharmaceuticals 
and to conduct international compari-
sons.11,15,17,22 More details on the data 
set are provided in the author’s data 
repository.23 
To extract data on systemic antibi-
otic formulations from the sales data-
base, we developed a comprehensive list 
of antibiotics used in human medicine. 
We used three sources: (i) WHO list 
of critically important antimicrobi-
als for human medicine, 2018 edi-
tion; (ii) WHO anatomical therapeutic 
chemical (ATC) code J01 (antibacteri-
als for systemic use); and (iii) WHO 
AWaRe classification, as presented in 
the 2019 WHO essential medicines 
list and in the WHO AWaRe classifica-
tion database.8,19,24 Included antibiotics 
were those defined as antibacterials for 
systemic use; we excluded antifungal 
and antiviral drugs, drugs solely for 
tuberculosis and topical formulations. 
We reviewed the full IQVIA database to 
identify any potentially missed or non-
classified systemic antibiotics; national 
data were reviewed by country experts.
Data analysis 
We estimated sales volumes in standard 
units (SU). SU refers to the number of 
standard dose units sold, where a dose 
is defined by IQVIA as one tablet or 
capsule for solid forms, one ampoule 
or vial for injectable forms, and 5 mL 
for syrup forms. We aggregated data at 
the year level by country and product. 
We defined each antibiotic product as 
Table 1. National data sources and coverage of pharmaceutical sales in the IQVIA 
multinational integrated data analysis system database
Country and audit type Data source Market 
coverage
France
Retail, sell-out Pharmacies with computerized systems 100%
Hospital, consumption Hospital trusts
Germany
Retail, sell-in Pharmacies and wholesalers 100%
Hospital, consumption Hospitals
Italy
Retail, sell-in Pharmacies and wholesalers 99%
Hospital, consumption Hospitals and local health authorities
Direct to patient, consumption Local health authorities
Japan
Retail, sell-in Wholesalers 100%
Hospital, sell-in Wholesalers
Spain




Retail, sell-in Deliveries of manufacturers, importers, and 
wholesalers
100%
Hospital, sell-in Deliveries of manufacturers, importers, and 
wholesalers
United Kingdom
Retail, sell-out Prescription data from pharmacies and 
direct sales panel
89%
Hospital, consumption National Health Service beds
United States
Combined retail and hospital, 
sell-in 
Wholesalers, mail service pharmacies, 
manufacturers, hospitals 
100%
Notes: IQVIA use a combination of local audits at different points of the distribution chain to collect data 
on pharmaceutical volumes; collection methods vary by country subject to local conditions and data 
availability. Audit type shows the data collection methods for each country (that is, retail or hospital sector 
and the specific sales channel). Sell-in refers to the indirect sales from manufacturers or wholesalers to 
either retail pharmacies (retail, sell-in) or hospital pharmacies (hospital, sell-in). Sales or consumption to the 
consumer are measured as sales from retail pharmacies to the patient (retail, sell-out) or distribution from 
hospital pharmacies to the patient (hospital, consumption). Through the IQVIA multinational integrated 
data analysis system local audits are standardized to allow cross-country comparability and analysis. 
Market coverage gives the percentage of the total national pharmaceutical market which the combined 
audits represent. For countries with < 100% coverage, IQVIA adjust according to a proprietary algorithm to 
estimate the probable total sales value based on the market share of the participating sources, such that the 
extract estimates 100% of consumption.
Sources: IQVIA multinational integrated data analysis system (IQVIA Inc., Durham, USA)20 and national audit 
data sources.
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Access, Watch, Reserve or Not Recom-
mended, according to the 2019 AWaRe 
categorization.8,19 As the classification 
did not include all antibiotics identi-
fied in the sales data, we created a 
fifth group – unclassified – containing 
all systemic antibiotics not listed. We 
determined antibiotic pharmacologi-
cal classifications using a combination 
of WHO ATC third- and fourth-level 
groups. Products and related AWaRe 
and antibiotic classifications are listed 
in the data repository.23
We used several metrics to explore 
sales patterns (Table 2). First, we calcu-
lated total antibiotic sales and antibiotic 
sales per person in each country, overall 
and by AWaRe category. We estimated 
per capita sales by linking total sales to 
total annual population estimates from 
the World Bank.25 Second, we calculated 
the percentage sales of each AWaRe 
category. Percentages were calculated 
as the number of SUs of antibiotics in 
each group divided by the total number 
of antibiotic SUs sold. The percentage 
of Access group antibiotics sold was 
described relative to the 60% target. 
We assessed sales trends between 2013 
and 2018 using simple linear regression 
by country and overall. Overall trends 
were estimated using the population-
weighted aggregate mean sales across 
all eight countries (details in the data 
repository).23 Next, we examined sales 
of specific antibiotic pharmacological 
classes, presenting the data as propor-
tions of total antibiotic sales and pro-
portions of the specific AWaRe category 
sale. Finally, to explore country-specific 
prescribing habits, we identified all 
products contributing to at least 3% of 
country-specific consumption in 2018 
and all products for which one country 
contributed more than 60% of total 
consumption across our sample.
We compiled additional data to 
analyse between-country differences in 
antibiotic sales. Country-level sociode-
mographic indicators were obtained 
from the World Bank.25 We obtained 
information on each country’s imple-
mentation of national antimicrobial 
policies from national reports and the 
WHO library of national action plans.26 
Lastly, to validate the results, we com-
pared country–year findings against 
European consumption data from the 
European Surveillance of Antimicrobial 
Consumption Network27 (see the data 
repository).23 We analysed all data using 
Stata, version 14.2 (StataCorp, College 
Station, USA).
Results
As of May 2020, all countries had imple-
mented an antimicrobial national action 
plan and three countries had adopted 
AWaRe for antibiotic use surveillance 
(Germany, Switzerland and the United 
Kingdom; Table 3). France implemented 
a similar categorization in 2013, before 
AWaRe was published. In 2018, the me-
dian annual sales of systemic antibiotics 
were 1.1 billion SU, ranging from 0.1 
billion in Switzerland to 6.0 billion in 
the USA. We found variability among 
the countries in 2018 levels of sales per 
capita, from the lowest in Germany and 
Switzerland (7.4 and 9.3 SU per capita, 
respectively) to the highest in France, 
Spain, the United Kingdom and USA 
(20.0, 18.2, 19.6 and 18.4 SU per capita, 
respectively). Overall antibiotic sales 
declined moderately between 2013 and 
2018, both in terms of total sales and 
sales per capita (Fig. 1; Fig. 2; Fig. 3; 
Fig. 4). In 2018, the median sales of 
Access group antibiotics were 10.9 SU 
per capita (range: 3.5–15.0) and median 
sales of antibiotics in the Watch group 
were 4.4 SU per capita (range: 2.2–12.3).
In 2018, the median percentage of 
Access group antibiotics sold was 68.3%, 
varying from 21.6% (439/2030 million 
SU) of total sales in Japan to 76.8% in 
the United Kingdom (1000/1302 million 
SU) and 77.2% in the USA (4649/6020 
million SU; Table 4; Fig. 1). When 
evaluated against the 60% target, five 
of the eight countries (France, Spain, 
Switzerland, the United Kingdom and 
USA) exceeded the 60% threshold and 
two were within 5.0 percentage points 
(Germany and Italy: 57.5% and 56.5%, 
respectively); only Japan’s figure was 
substantially lower. 
The percentage of Access group 
antibiotics sold increased over 2013–
2018 in all countries by a population-
Table 2. Outcome definitions used in the study of antibiotic sales in eight high-income 
countries
Outcome Level of analysis Definition
Total annual sales, SU Overall Total sales of systemic antibiotics 
per year in SU
Annual sales per 
capita, SU per capita
Overall, by AWaRe category 
and by pharmacological class
No. of SU sold per year divided 
by the country–year population 
estimate derived from the World 
Bank25
Relative sales, % of 
total sales
By AWaRe category and by 
pharmacological class
No. of SU sold in each group divided 
by the total no. of antibiotic SU sold 
in the given year (multiplied by 100)
Relative sales, % of 
AWaRe category sales
By pharmacological class No. of SU sold of the specific 
antibiotic class and AWaRe category 
divided by the no. of AWaRe 
category SU sold in the given year 
(multiplied by 100)
≥ 3% sales indicator By individual antibiotic Products accounting for ≥ 3% of 
country-specific consumption in 
2018. Calculated as the no. of SU 
sold of each antibiotic divided by 
the total no. of SU by country in 
2018
Single country 
indicator, ≥ 60% of 
total sales
By individual antibiotic Products accounting for ≥ 60% of 
per capita consumption. Calculated 
as the no. of per capita SU sold 
for a particular antibiotic in each 
country divided by the total per 
capita SU over all countries in 2018. 
Calculated for all products identified 
in the ≥ 3% consumption list
AWaRe: Access, Watch and Reserve classification; SU: standard units. 
Note: The unit for all analyses was at the country–year level. We identified AWaRe antibiotic categories 
according to the World Health Organization 2019 classification.8 We categorized pharmacological class 
according to the WHO anatomical therapeutic chemical third and fourth levels (see the data repository for 
classifications).23
553Bull World Health Organ 2021;99:550–561| doi: http://dx.doi.org/10.2471/BLT.20.270934
Research
Progress towards antibiotic use targetsBryony Simmons et al.
weighted average annual change of 0.9 
percentage points (P < 0.001; Table 4; 
Fig. 5). Variation arose mainly between 
the Access and Watch groups, with sales 
of these categories accounting from a 
median of 98.8% of sales (range: 97.3–
99.7). Reserve group antibiotics made 
up less than 1.5% of sales in all coun-
tries and years (median in 2018: 0.4%; 
range: 0.2–1.2). Not Recommended and 
unclassified products accounted for a 
small proportion of total sales (median 
in 2018: 0.5%; range: 0.1–2.2).
Sales by pharmacological class and 
AWaRe category are shown in the data 
repository.23 Access group penicillins 
accounted for a median 70.7% (range: 
47.6–86.6) of Access group antibiotics 
sold in 2018 and 48.8% (range: 13.9–
64.2) of total antibiotic sales. The sales 
pattern of Access group penicillin varied 
between countries, with most classi-
fied as extended-spectrum penicillins 
(median: 31.8% of Access group; range: 
19.3–52.0) or extended-spectrum with 
a β-lactamase inhibitor (median: 22.0% 
of Access group; range: 8.8–67.0). The 
United Kingdom had a higher use of 
narrow-spectrum β-lactamase-sensitive 
and -resistant penicillins at 27.4% 
(357/1302 million SU) of total sales. 
Japan had lower relative sales of Access 
group penicillins than other countries 
at 13.9% (283/2030 million SU) of total 
sales. Sulfonamides were the second 
most sold Access group antibiotic 
(median: 8.0% of Access group; range: 
3.3–15.0; 4.0% of total; range: 2.2–7.9) 
followed by tetracyclines (median: 7.2% 
of Access group; range: 2.0–13.8; 5.2% 
of total; range: 1.1–10.7). The most 
frequently sold Watch group antibiotics 
were cephalosporins (median: 24.9% 
of Watch group; range: 2.0–43.2; 6.8% 
of total; range: 0.4–33.3), fluoroquino-
lones (median 24.6% of Watch group; 
range: 10.5–42.5; 8.9% of total; range: 
2.3–12.6), and macrolides (median: 
25.4% of Watch group; range: 17.2–42.2; 
6.7% of total; range: 5.2–23.8). In Ja-
pan, Watch cephalosporins sold more 
than in other countries both in terms 
of percentage of Watch group antibiot-
ics (43.2%; 675/1562 million SU) and 
overall antibiotic sales (33.3%; 675/2030 
million SU), driven by high sales of 
third-generation cephalosporins. The 
most widely sold Reserve group antibi-
otics were polymyxins (median: 47.8% 
of Reserve group; range: 3.1–72.0) 
and oxazolidinones (median: 20.5% of 
Reserve group; range: 2.7–45.3); these 
made up a very small proportion of 
overall sales (< 0.5%).
Amoxicillin was the only product 
that accounted for ≥ 3% of sales in all 
countries assessed (median: 19.0% of 
total consumption; range: 10.0–34.0; 2.8 
SU per capita); amoxicillin/clavulanic 
acid sales were ≥ 3% in all countries 
except Japan (median 14.4%; range: 
1.9–37.7; 2.0 SU per capita) as shown in 
the data repository.23 In total, nine prod-
ucts were sold primarily in one country 
(defined as one country accounting for 
≥ 60% of total consumption); three were 
sold exclusively in one country: pris-
tinamycin (France), cefcapene pivoxil 
(Japan) and oxytetracycline (the United 
Kingdom).
For external validity, we compared 
comparable country–year results against 
European Centre for Disease Prevention 
and Control network data for France, 
Italy, Spain and the United Kingdom. 
These results showed a strong correla-
tion and support the validity of our 
results (see the data repository).23
Discussion
It is encouraging that in 2018 several 
of the countries studied achieved the 
WHO 60% Access group target, with a 
median percentage sales of Access group 
antibiotics across the eight countries of 
68%. Of the three countries not meeting 
the target, Italy and Germany narrowly 
missed it, while Japan’s proportion was 
notably lower. Most countries made 
progress in optimizing antibiotic sales 
between 2013 and 2018, both in terms of 
an increase in the relative sales of Access 
group products and a decrease in per 
person sales of antibiotics.
Table 3. Country characteristics and antibiotic policies 





WHO Region Europe Europe Europe Western 
Pacific
Europe Europe Europe Americas
Population, total in millions 67.0 82.9 60.4 126.5 46.7 8.5 66.5 327.2
GDP per capita, PPP current 
thousands of international 
dollars
45.9 54.3 42.1 43.3 40.9 68.9 46.2 62.6
Health expenditure 
per capita, PPP current 
thousands of international 
dollars
5.3 6.1 3.6 4.5 3.6 8.1 4.6 10.6
Health expenditure, % of 
GDP
11.2 11.2 8.8 10.9 8.9 12.2 9.8 16.9
Antibiotic policies
National action plan on 
antibiotic use
Yes Yes Yes Yes Yes Yes Yes Yes
Adopted AWaRe 
categorization in national 
policy
No, use similar 
categorization
Yes No No No Yes Yes, adapted No
AWaRe: Access, Watch and Reserve classification; GDP: gross domestic product; PPP: purchasing power parity; WHO: World Health Organization.
Note: Data shown are from the most recent year available between 2013 and 2018. 
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The AWaRe classification and as-
sociated target provides a framework for 
simplified and standardized antibiotic 
surveillance and has the support of the 
G20 group of governments and central 
bank governors.28,29 Some of the studied 
countries have already adopted AWaRe 
for surveillance of antibiotics in an ef-
fort to translate international guidance 
into effective stewardship.28,30 To most 
effectively inform practice, England and 
Scotland in the United Kingdom have 
adapted the index to their local context, 
re-categorizing certain products, based 
on local resistance profiles, antibiotic 
use and the health-care setting.30 Preced-
ing AWaRe, France initiated a similar 
categorization with associated targets 
and incentivized quality improvement 
mechanisms.31,32
In 2018, WHO released the first 
global report applying the 2017 AWaRe 
classification to evaluate 2015 levels 
of antibiotic use.18 We build upon this 
report and other studies, using the 
updated 2019 AWaRe categorization 
and more recent data through to 2018, 
and providing a detailed analysis of 
specific consumption patterns.15,18 In 
comparison with these studies, we 
observed marginally higher relative 
sales of Access group antibiotics, while 
the intra-country differences and time 
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AWaRe: Access, Watch and Reserve classification.
Note: The figure shows the percentage of the total number of systemic antibiotic standard units sold, by 2019 World Health Organization AWaRe categories.19 
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trends remained similar. Our analysis 
highlights cross-country differences in 
per capita antibiotic sales. For example, 
consistent with other reports,11 Germany 
and Switzerland sold relatively small 
quantities of antibiotics. Across coun-
tries, most heterogeneity was observed 
between Access and Watch group an-
tibiotics; sales of Reserve category and 
Not Recommended products were low. 
Cross-country comparisons allow for 
some inferences about the appropriate-
ness of antibiotic sales but should be in-
terpreted with caution due to differences 
in burden, resistance profiles, treatment 
guidelines and health systems.13,33,34
Japan stands out as having a differ-
ing pattern of antibiotic consumption. 
We found lower relative sales of Ac-
cess group broad-spectrum penicillins 
and higher sales of Watch category 
antibiotics, predominantly driven by 
high relative sales of third-generation 
cephalosporins and, to a lesser extent, 
macrolides and fluoroquinolones. These 
findings corroborate other studies of 
antimicrobial sales in Japan.35,36 The 
differences in sales patterns have sev-
eral potential explanations. Many of the 
products sold in Japan were of Japanese 
origin and some products were rarely 
sold in other countries. This pattern 
might suggest a difference in regulatory 
Fig. 2. Per capita antibiotic sales in eight high-income countries by AWaRe category, 2013–2018
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AWaRe: Access, Watch and Reserve classification; SU: standard units.
Note: The figure shows the number of standard units of antibiotics sold per capita, by 2019 World Health Organization AWaRe categories.19
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requirements that discourage Japanese 
companies from seeking market autho-
rization outside of Asia and likewise 
delaying or preventing uptake of prod-
ucts of non-Japanese origin. Japanese 
authorities may also prefer marketing 
strategies focusing on the domestic 
market.37,38 Differences in resistance 
patterns, patient demographics and 
cultural factors might also contribute to 
a different uptake of products in Japan. 
The Japanese antimicrobial national ac-
tion plan promotes optimization of drug 
use and targets a reduced consumption 
of cephalosporins, fluoroquinolones and 
macrolides by 50% in 2020 from the 
2013 baseline level.39 We observed prog-
ress towards this target with around 15% 
reduction of cephalosporin, fluoroqui-
nolone and macrolide sales, but further 
action is required to meet targets.
The 60% Access group target pro-
vides a simple metric to monitor Access 
and promote responsible antibiotic 
use, but an emphasis on relative con-
sumption alone could have unintended 
consequences on absolute consumption. 
In Germany, the Access group target 
was narrowly missed. The target could 
be achieved by a switch from second-
generation Watch group cephalosporins 
to the Access group first-generation 
cephalosporins, but likewise it could be 
met through unnecessarily increasing 
sales of Access group products. Japan, 
despite a low Access group index, had 
relatively low total antibiotic sales and 
relatively low reported rates of antibiotic 
resistance. The European Centre for 
Disease Prevention and Control list of 
indicators for monitoring antibiotic con-
sumption utilizes an absolute measure as 
the primary indicator of consumption to 
consider the amount of antimicrobials 
used.40 Secondary indicators, such as 
the ratio of broad-spectrum to narrow-
spectrum antibiotics, overlap largely 
with the AWaRe Watch and Reserve 
group categories. Our findings and com-
plementary assessment tools illustrate 
the importance for future stewardship 
policies in combining the Access group 
target with measures of total absolute 
consumption to give a more nuanced 
view of antibiotic stewardship.
Our study had some limitations. We 
estimated sales using SU, a standard-
ized measure within the data source 
representing a single dose unit of sales. 
This method differs from the WHO 












































Notes: Numeric estimates provided to the right of each trend line are the linear regression coefficient and 
can be interpreted as the estimated average annual change in the outcome for each country and for the 
weighted-aggregate. Weighted-aggregate is the population-weighted mean over the eight countries. 
Values are presented in the data repository.23 
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Notes: Numeric estimates provided to the right of each trend line are the linear regression coefficient and 
can be interpreted as the estimated average annual change in the outcome for each country and for the 
weighted-aggregate. Weighted-aggregate is the population-weighted mean over the eight countries. 
Values are presented in the data repository.23 
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consumption surveillance, which uses 
the ATC/defined daily dose method of 
calculation.18 SU provide an easily inter-
pretable and standardized measure that 
does not require assumptions of sales 
which may not be correct in all settings 
and case-mixes of patients.17,41 However, 
the use of SU may limit comparisons 
across populations, particularly when 
dosing regimens and durations are vari-
able, possibly biasing results towards the 
sales of antibiotics with longer dura-
tions or frequencies of dosing.17 As in 
previous studies, we observed a strong 
correlation between defined daily doses 
and SU when comparing our results 
with European Surveillance of Antimi-
crobial Consumption Network data for 
European countries. Our findings show 
similar trends to the WHO report18 and 
other recent studies.11,14,17
The use of sales data has certain 
limitations. Foremost, we did not study 
individual-level consumption. We could 
not determine patient characteristics 
and indications for treatment: factors 
critical to determining the appropriate-
ness of prescribing and antibiotic use. 
Second, sales data may not be represen-
tative of the entire market – particularly 
for those countries where the data covers 
less than 100% of the pharmaceutical 
market – and the IQVIA algorithm to 
produce nationally representative esti-
mates is not publicly available. Third, 
it may not be possible to disaggregate 
data by sector, facility and subnational 
geographies. Finally, the use of aggre-
gate sales data provides a simple and 
standardized proxy for antibiotic con-
sumption but should be complemented 
by analysis of data sources that enable 
conclusions to be drawn about the ap-
propriateness of antibiotic use at the 
patient level.18 Future studies should 
assess consumption using sources such 
as prescribing data, dispensing records, 
and insurance and reimbursement 
records. Indicators using these data 
could more closely reflect the quality of 
antimicrobial prescribing.
Finally, while including a smaller 
subset of countries has allowed for a 
more in-depth analysis of antibiotic 
sales practices in this selection of highly 
developed countries, the findings need 
to be complemented by global data and 
more heterogeneous settings. Global in-
creases in antibiotic consumption have 
been shown to be driven by rapid in-
creases in consumption of Watch group 
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middle-income countries, highlighting 
the need for broader analyses to support 
stewardship efforts.15 In addition, future 
analyses could more deeply explore 
factors associated with differences in 
sales, how AWaRe is being adopted 
and adapted to national contexts and 
stewardship plans, and the impact of 
the introduction of AWaRe on antibiotic 
sales and resistance patterns.
Monitoring antibiotic consumption 
is an essential policy action highlight-
ing potential areas where changes are 
needed to reduce the risk of antimi-
crobial resistance. As countries adopt 
the WHO AWaRe framework, there is 
a need to assess changes in antibiotic 
sales and use over time, and whether the 
WHO Access target is sufficient to pre-
serve antibiotic efficacy across a range 
of infections or should be expanded. 
All countries should consider adapt-
ing the AWaRe classification and target 
to individual settings, with country-
specific targets unambiguously reported 
in antimicrobial national action plans. 
Additional metrics, such as those focus-
ing on absolute consumption, and more 
ambitious targets are needed to better 
adapt appropriateness of antibiotic 
use, particularly in mature health-care 
systems. ■
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ملخص
التقدم نحو أهداف استخدام املضادات احليوية يف ثامين دول مرتفعة الدخل
مرتفعة  دول  ثامين  يف  احليوية  املضادات  مبيعات  مقارنة  الغرض 
 (WHO) العاملية  الصحة  منظمة  تصنيف  باستخدام  الدخل 
لإلتاحة واملراقبة واالحتياطي (AWaRe) لعام 2019، واهلدف 
املتمثل يف استهالك %60 من املضادات احليوية من فئة الوصول.
الطريقة قمنا بتحليل البيانات من قاعدة البيانات التجارية ملبيعات 
وأملانيا  واليابان  وإيطاليا  فرنسا  يف  املنتظمة  احليوية  املضادات 
وأيرلندا  العظمى  لربيطانيا  املتحدة  واململكة  وسويرسا  وأسبانيا 
إىل   2013 األعوام  األمريكية، خالل  املتحدة  والواليات  الشاملية 
 2019 لفئات  وفًقا  احليوية  املضادات  بتصنيف  وقمنا   .2018
هبا.  املوىص  وغري  واالحتياطي،  واملراقبة،  اإلتاحة،   :AWaRe
قمنا بقياس مبيعات املضادات احليوية للفرد يف الوحدات القياسية 
كنسبة  اإلتاحة  جمموعة  مبيعات  حساب  وكذلك  للفرد،   (SU)
مئوية من إمجايل مبيعات املضادات احليوية.
2018، تراوحت مبيعات املضادات احليوية للفرد  النتائج يف عام 
من 7.4 وحدة قياسية (سويرسا) إىل 20.0 وحدة قياسية (فرنسا)؛ 
 10.9 اإلتاحة  ملجموعة  احليوية  املضادات  مبيعات  متوسط  كان 
مبيعات  انخفض   .(15.0 إىل   3.5 (النطاق:  للفرد  قياسية  وحدة 
كانت   .2018 إىل   2013 من  الفرتة  خالل  معتدل  بشكل  الفرد 
متوسط النسبة املئوية للمضادات احليوية ملجموعة الوصول 68% 
(النطاق: 22 إىل %77)، وزادت نسبة جمموعة الوصول يف معظم 
اهلدف  دول  مخس  وجتاوزت  و2018.   2013 عامي  بني  الدول 
املتمثل يف %60؛ بينام أخفقت دولتان يف حتقيق هذا اهلدف بفارق 
املضادات  مبيعات  كانت  وإيطاليا).  أملانيا  يف   55%  <) ضئيل 
للمبيعات  نتيجًة   ،(22%) منخفضة  اليابان  يف  املتاحة  احليوية 
املرتفعة نسبًيا من مركبات السيفالوسبورين واملاكروليد الفموية.
تسمح  أن  يمكنها  الوصفات  يف  تغيريات  بتحديد  قمنا  االستنتاج 
املجموعة  هدف  إن  العاملية  الصحة  منظمة  هدف  بتحقيق  للدول 
الوطنية  السياسات  لتوعية  إطـاًرا  يوفر   ،60% البالغ  املتاحة 
أكثر  وقيم  مطلقة،  بتدابري  استكامله  ويمكن  احليوية،  للمضادات 
طموًحا يف أوضاع حمددة.، وقيم أكثر طموًحا يف أوضاع حمددة.
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Notes: The linear regression coefficients for the trends are presented in Table 4. Weighted-aggregate is the 
population-weighted mean over the eight countries. Values are presented in the data repository.23 
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摘要
八个高收入国家实现抗生素使用目标的进展
目的 旨在根据 2019 年世界卫生组织 (WHO) 可用、慎
用和备用 (AWaRe) 分级原则和 60% 可用级抗生素消费
目标，比较 8 个高收入国家的抗生素销售情况。
方法 我们分析了 2013 年至 2018 年期间德国、法国、
美国、日本、瑞士、西班牙、意大利和英国全身性抗





结果 2018 年，人均抗生素销售额为 7.4 SU（瑞士）至 
20.0 SU（法国）不等 ；可用级抗生素的平均销售额为
人均 10.9 SU（范围 ：3.5–15.0）。2013-2018 年间人均
销售额有所下降。可用级抗生素的中位百分比为 68%
（范围 ：22–77%）；2013 年至 2018 年间，大多数国家
的可用级抗生素消费比例有所上升。有 5 个国家超过









Progrès accomplis en matière de consommation d'antibiotiques dans huit pays à hauts revenus 
Objectif Comparer les ventes d'antibiotiques dans huit pays à hauts 
revenus à l'aide de la classification AWaRe (Access, Watch et Reserve) 
mise en place en 2019 par l'Organisation mondiale de la Santé, ainsi 
que de l'objectif de consommation de 60% fixé pour les antibiotiques 
de la catégorie Access.
Méthodes Nous avons analysé les informations issues d'une base 
de données commerciales concernant la vente d'antibiotiques 
systémiques entre 2013 et 2018 en Allemagne, en Espagne, aux États-
Unis d'Amérique, en France, en Italie, au Japon, au Royaume-Uni de 
Grande-Bretagne et d'Irlande du Nord et en Suisse. Nous avons réparti 
ces antibiotiques selon les catégories AWaRe 2019: Access (antibiotiques 
dont l'accessibilité est essentielle), Watch (antibiotiques à utiliser 
sélectivement) et Reserve (antibiotiques de réserve, non recommandés). 
Nous avons mesuré les ventes d'antibiotiques en unités standard (SU) 
par habitant, et calculé celles de la catégorie Access sous forme de 
pourcentage des ventes totales.
Résultats En 2018, les ventes d'antibiotiques par habitant étaient 
comprises entre 7,4 SU (Suisse) et 20,0 SU (France); la valeur médiane 
des ventes d'antibiotiques Access s'élevait à 10,9 SU par habitant (écart: 
3,5-15,0). Les ventes par habitant ont diminué modérément au fil des 
ans entre 2013 et 2018. Le pourcentage médian des antibiotiques Access 
était de 68% (écart: 22–77%); dans la plupart des pays, leur pourcentage 
a augmenté entre 2013 et 2018. Cinq pays dépassaient l'objectif de 
60%; deux autres s'en approchaient (> 55% en Allemagne et en Italie). 
La vente d'antibiotiques Access au Japon était faible (22%) en raison 
d'une forte consommation de macrolides et de céphalosporines orales.
Conclusion Nous avons constaté une évolution dans les prescriptions, 
ce qui pourrait permettre aux pays d'atteindre l'objectif de l'OMS. Une 
limite de consommation d'antibiotiques Access fixée à 60% pourrait 
servir d'orientation aux politiques nationales en la matière, et être 
complétée par des mesures absolues et des chiffres plus ambitieux 
dans des contextes spécifiques.
Резюме
Прогресс в достижении целевых показателей использования антибиотиков в восьми странах с 
высоким уровнем дохода
Цель Сравнить продажи антибиотиков в восьми странах с 
высоким уровнем дохода, используя классификацию Всемирной 
организации здравоохранения (ВОЗ) 2019 года для антибиотиков 
AWaRe («доступ», «наблюдение» и «резерв»), а также прогресс 
в достижении цели увеличить долю глобального потребления 
антибиотиков на 60% в группе «доступ».
Методы Авторы проанализировали данные из коммерческой базы 
данных о продажах системных антибиотиков в Германии, Испании, 
Италии, Соединенном Королевстве Великобритании и Северной 
Ирландии, Соединенных Штатах Америки, Франции, Швейцарии 
и в Японии за 2013–2018 годы. Были классифицированы 
антибиотики по категориям AWaRe 2019: «доступ», «наблюдение», 
«резерв» и «нерекомендуемые». Авторы измерили продажи 
антибиотиков на душу населения в стандартных единицах (СЕ) 
на душу населения и рассчитали продажи в группе «доступ» как 
процент от общих продаж антибиотиков.
Результаты В 2018 году продажи антибиотиков на душу населения 
составляли от 7,4 СЕ (Швейцария) до 20,0 СЕ (Франция); медиана 
продаж антибиотиков в группе «доступ» составила 10,9 СЕ 
на душу населения (диапазон: 3,5–15,0). Продажи на душу 
населения в 2013–2018 годах умеренно снизились. Медиана 
процентной доли антибиотиков в группе «доступ» составила 
68% (диапазон: 22–77%); процентная доля в группе «доступ» 
увеличилась в большинстве стран в период с 2013 по 2018 год. 
Пять стран превысили показатель в 60%; две страны чуть не 
упустили этот показатель (> 55% в Германии и Италии). Продажи 
антибиотиков в группе «доступ» в Японии были низкими (22%), 
что было обусловлено относительно высокими продажами 
пероральных цефалоспоринов и макролидов.
Вывод Мы определили изменения в назначениях, что позволит 
странам достичь целевого показателя ВОЗ. Достижение 60% в 
группе «доступ» служит основой для информационного 
обеспечения национальной политики в отношении антибиотиков, 
которую можно было бы дополнить абсолютными показателями 
и более амбициозными значениями в определенных условиях.
560 Bull World Health Organ 2021;99:550–561| doi: http://dx.doi.org/10.2471/BLT.20.270934
Research
Progress towards antibiotic use targets Bryony Simmons et al.
Resumen
Avances hacia los objetivos de uso de antibióticos en ocho países con ingresos altos
Objetivo Comparar las ventas de antibióticos en ocho países con 
ingresos altos utilizando la clasificación de acceso, vigilancia y reserva 
(AWaRe) de la Organización Mundial de la Salud (OMS) de 2019 y el 
objetivo de consumo del 60% de los antibióticos de la categoría de 
acceso.
Métodos Analizamos los datos de una base de datos comercial de 
ventas de antibióticos sistémicos en Francia, Italia, Japón, Alemania, 
España, Suiza, Reino Unido de Gran Bretaña e Irlanda del Norte y 
Estados Unidos de América durante los años 2013-2018. Clasificamos 
los antibióticos según las categorías AWaRe de 2019: acceso, vigilancia, 
reserva y no recomendado. Medimos las ventas de antibióticos per 
cápita en unidades estándar (SU) per cápita y calculamos las ventas del 
grupo de acceso como porcentaje de las ventas totales de antibióticos.
Resultados En 2018, las ventas per cápita de antibióticos oscilaron entre 
7,4 SU (Suiza) y 20,0 SU (Francia); la media de las ventas de antibióticos 
del grupo de acceso fue de 10,9 SU per cápita (rango: 3,5-15,0). Las 
ventas per cápita disminuyeron moderadamente durante 2013-2018. 
La media del porcentaje de antibióticos del grupo de acceso fue del 
68% (rango: 22-77%); la proporción del grupo de acceso aumentó en 
la mayoría de los países entre 2013 y 2018. Cinco países superaron el 
objetivo del 60%; dos países lo incumplieron por un escaso margen 
(> 55% en Alemania e Italia). Las ventas de antibióticos de acceso en 
Japón fueron bajas (22%), impulsadas por una venta relativamente alta 
de cefalosporinas orales y macrólidos.
Conclusión Hemos identificado cambios en la prescripción que podrían 
permitir a los países alcanzar el objetivo de la OMS. El objetivo del 60% 
del grupo de acceso proporciona un marco para informar las políticas 
nacionales de antibióticos y podría complementarse con medidas 
absolutas y valores más ambiciosos en entornos específicos.
References
1. Antimicrobial resistance: global report on surveillance. Geneva: World 
Health Organization; 2014. Available from: https:// www .who .int/ 
drugresistance/ documents/ surveillancereport/ en/ [cited 2019 Aug 8].
2. Laxminarayan R, Amábile-Cuevas CF, Cars O, Evans T, Heymann DL, Hoffman 
S, et al. UN High-Level Meeting on antimicrobials – what do we need? 
Lancet. 2016 Jul 16;388(10041):218–20. doi: http:// dx .doi .org/ 10 .1016/ 
S0140 -6736(16)31079 -0 PMID: 27479554
3. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. 
Antibiotic resistance – the need for global solutions. Lancet Infect Dis. 2013 
Dec;13(12):1057–98. doi: http:// dx .doi .org/ 10 .1016/ S1473 -3099(13)70318 -9 
PMID: 24252483
4. Global action plan on antimicrobial resistance. Geneva: World Health 
Organization; 2015. Available from: https:// www .who .int/ antimicrobial 
-resistance/ publications/ global -action -plan/ en/ [cited 2019 Aug 8]. 
5. Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, et al.; 21st 
WHO Expert Committee on Selection and Use of Essential Medicines. 
Classifying antibiotics in the WHO Essential Medicines List for optimal use – 
be AWaRe. Lancet Infect Dis. 2018 Jan;18(1):18–20. doi: http:// dx .doi .org/ 10 
.1016/ S1473 -3099(17)30724 -7 PMID: 29303731
6. The selection and use of essential medicines: report of the WHO Expert 
Committee, 2017 (including the 20th WHO Model List of Essential 
Medicines and the 6th WHO Model List of Essential Medicines for Children). 
Geneva: World Health Organization; 2017. Available from: https:// www .who 
.int/ medicines/ publications/ essentialmedicines/ trs -1006 -2017/ en/ [cited 
2019 Aug 8]. 
7. AWaRe policy brief. Geneva: World Health Organization; 2019. Available 
from: https:// apps .who .int/ iris/ handle/ 10665/ 327957 [cited 2019 Oct 2].
8. The selection and use of essential medicines: report of the WHO Expert 
Committee on Selection and Use of Essential Medicines, 2019 (including 
the 21st WHO Model List of Essential Medicines and the 7th WHO Model 
List of Essential Medicines for Children). Geneva: World Health Organization; 
2019. Available from: https:// www .who .int/ medicines/ publications/ 
essentialmedicines/ en/ [cited 2020 Jan 15]. 
9. In the face of slow progress, WHO offers a new tool and sets a target to 
accelerate action against antimicrobial resistance. Geneva: World Health 
Organization; 2019.
10. Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, et al.; EML 
Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness 
and discouraging inappropriate antibiotic use-the new 2019 Essential 
Medicines List becomes a global antibiotic stewardship tool. Lancet Infect 
Dis. 2019 Dec;19(12):1278–80. doi: http:// dx .doi .org/ 10 .1016/ S1473 
-3099(19)30532 -8 PMID: 31782385
11. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et 
al. Global antibiotic consumption 2000 to 2010: an analysis of national 
pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742–50. doi: 
http:// dx .doi .org/ 10 .1016/ S1473 -3099(14)70780 -7 PMID: 25022435
12. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al.; 
Global-PPS network. Antimicrobial consumption and resistance in adult 
hospital inpatients in 53 countries: results of an internet-based global point 
prevalence survey. Lancet Glob Health. 2018 Jun;6(6):e619–29. doi: http:// 
dx .doi .org/ 10 .1016/ S2214 -109X(18)30186 -4 PMID: 29681513
13. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, 
et al. Global increase and geographic convergence in antibiotic 
consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018 Apr 
10;115(15):E3463–70. doi: http:// dx .doi .org/ 10 .1073/ pnas .1717295115 
PMID: 29581252
14. Jackson C, Hsia Y, Bielicki JA, Ellis S, Stephens P, Wong ICK, et al. Estimating 
global trends in total and childhood antibiotic consumption, 2011–2015. 
BMJ Glob Health. 2019 Feb 27;4(1):e001241. doi: http:// dx .doi .org/ 10 .1136/ 
bmjgh -2018 -001241 PMID: 30899565
15. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra, Pulcini, et 
al. Assessment of WHO antibiotic consumption and access targets in 76 
countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infect 
Dis. 2020; doi: http:// dx .doi .org/ 10 .1016/ S1473 -3099(20)30332 -7 PMID: 
32717205
16. Hsia Y, Lee BR, Versporten A, Yang Y, Bielicki J, Jackson C, et al.; GARPEC 
and Global-PPS networks. Use of the WHO Access, Watch, and Reserve 
classification to define patterns of hospital antibiotic use (AWaRe): an 
analysis of paediatric survey data from 56 countries. Lancet Glob Health. 
2019 Jul;7(7):e861–71. doi: http:// dx .doi .org/ 10 .1016/ S2214 -109X(19)30071 
-3 PMID: 31200888
17. Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. 
Consumption of oral antibiotic formulations for young children according 
to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis 
of sales data from 70 middle-income and high-income countries. Lancet 
Infect Dis. 2019 Jan;19(1):67–75. doi: http:// dx .doi .org/ 10 .1016/ S1473 
-3099(18)30547 -4 PMID: 30522834
18. WHO report on surveillance of antibiotic consumption: 2016–2018 early 
implementation. Geneva: World Health Organization; 2018. Available from: 
https:// apps .who .int/ iris/ handle/ 10665/ 277359 [cited 2020 Dec 19].
19. The 2019 WHO AWaRe classification of antibiotics for evaluation and 
monitoring of use (WHO/essential medicines list/IAU/2019.11). Geneva: 
World Health Organization; 2019. Available from: https:// www .who 
.int/ medicines/ news/ 2019/ WHO _releases2019AWaRe _classification 
_antibiotics/ en/ [cited 2020 Jan 20].
20. Cook MN. Estimating national drug consumption using data at different 
points in the pharmaceutical supply chain. Pharmacoepidemiol Drug Saf. 
2006 Oct;15(10):754–7. doi: http:// dx .doi .org/ 10 .1002/ pds .1309 PMID: 
16989003
21. MIDAS® [internet]. Durham: IQVIA; 2021. Available from: https:// www .iqvia 
.com/ solutions/ commercialization/ brand -strategy -and -management/ 
market -measurement/ midas [cited 2021 Apr 8].
561Bull World Health Organ 2021;99:550–561| doi: http://dx.doi.org/10.2471/BLT.20.270934
Research
Progress towards antibiotic use targetsBryony Simmons et al.
22. Klein EY, Tseng KK, Pant S, Laxminarayan R. Tracking global trends in the 
effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ 
Glob Health. 2019 Apr 11;4(2):e001315. doi: http:// dx .doi .org/ 10 .1136/ 
bmjgh -2018 -001315 PMID: 31139449
23. Simmons B, Ariyoshi K, Ohmagari N, Pulcini C, Huttner B, Gandra S, et al. 
Supplementary webappendix: Progress towards WHO AWaRe targets [data 
repository]. London: figshare; 2019. doi: http:// dx .doi .org/ 10 .6084/ m9 
.figshare .14384588doi: http:// dx .doi .org/ 10 .6084/ m9 .figshare .14384588
24. Critically important antimicrobials for human medicine, 6th revision. 
Geneva: World Health Organization; 2019. Available from: https:// www .who 
.int/ foodsafety/ publications/ antimicrobials -sixth/ en/ [cited 2020 Jan 20].
25. World Bank indicators [internet]. Washington: The World Bank: 2019. 
Available from: https:// data .worldbank .org/ indicator [cited 2019 Dec 10].
26. Library of national action plans [internet]. Geneva: World Health 
Organization; 2019. Available from: https:// www .who .int/ antimicrobial 
-resistance/ national -action -plans/ library/ en/ [cited 2019 Dec 10].
27. Antimicrobial consumption database (ESAC-Net) [internet]. Solna: European 
Centre for Disease Prevention and Control; 2019. Available from: https:// 
www .ecdc .europa .eu/ en/ antimicrobial -consumption/ surveillance -and 
-disease -data/ database [cited 2019 Dec 10].
28. Adopt AWaRe: handle antibiotics with care. Geneva: World Health 
Organization; 2019. Available from: https:// adoptaware .org/ assets/ pdf/ 
aware _brochure .pdf [cited 2020 Jun 18].
29. Declaration. G20 Meeting of Health Ministers 2018, 4 October 2018, Mar del 
Plata, Argentina. Cancún: Group of 20; 2018. Available from: http:// www 
.g20 .utoronto .ca/ 2018/ 2018 -10 -04 -health .pdf [cited 2020 Jun 18]. 
30. Budd E, Cramp E, Sharland M, Hand K, Howard P, Wilson P, et al. Adaptation 
of the WHO Essential Medicines List for national antibiotic stewardship 
policy in England: being AWaRe. J Antimicrob Chemother. 2019 Nov 
1;74(11):3384–9. doi: http:// dx .doi .org/ 10 .1093/ jac/ dkz321 PMID: 31361000
31. [Characterization of antibiotics considered to be “critical”: first reflexions 
on their characteristics (information point)] [internet]. Saint-Denis Cedex: 
Agence nationale de sécurité du medicament; 2013. French. Available from: 
https:// archiveansm .integra .fr/ afssaps/ S -informer/ Points -d -information 
-Points -d -information/ Les -antibiotiques -consideres -comme -critiques 
-premieres -reflexions -sur -leur -caracterisation -Point -d -information [cited 
2020 Mar 16].
32. Howard P, Huttner B, Beovic B, Beraud G, Kofteridis DP, Pano Pardo J, et al.; 
ESGAP Indicators Working Group. ESGAP inventory of target indicators 
assessing antibiotic prescriptions: a cross-sectional survey. J Antimicrob 
Chemother. 2017 Oct 1;72(10):2910–4. doi: http:// dx .doi .org/ 10 .1093/ jac/ 
dkx243 PMID: 29091207
33. Gianino MM, Lenzi J, Bonaudo M, Fantini MP, Ricciardi W, Damiani G. 
Predictors and trajectories of antibiotic consumption in 22 EU countries: 
Findings from a time series analysis (2000–2014). PLoS One. 2018 Jun 
22;13(6):e0199436. doi: http:// dx .doi .org/ 10 .1371/ journal .pone .0199436 
PMID: 29933377
34. Pulcini C, Beovic B, Cavalié P, Deptula A, Dyar O, Gyssens I, et al.; ESGAP 
AMOXDOSE working group. Amoxicillin dosing recommendations are very 
different in European countries: a cross-sectional survey. Clin Microbiol 
Infect. 2017 Jun;23(6):414–5. doi: http:// dx .doi .org/ 10 .1016/ j .cmi .2016 .11 
.013 PMID: 27890458
35. Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national 
antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 
2018 Jun;24(6):414–21. doi: http:// dx .doi .org/ 10 .1016/ j .jiac .2018 .01 .003 
PMID: 29428566
36. Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, et al. Japanese 
antimicrobial consumption surveillance: first report on oral and parenteral 
antimicrobial consumption in Japan (2009–2013). J Glob Antimicrob Resist. 
2016 Dec;7:19–23. doi: http:// dx .doi .org/ 10 .1016/ j .jgar .2016 .07 .002 PMID: 
27973324
37. Kållberg C, Årdal C, Salvesen Blix H, Klein E, M Martinez E, Lindbæk M, et 
al. Introduction and geographic availability of new antibiotics approved 
between 1999 and 2014. PLoS One. 2018 Oct 16;13(10):e0205166. doi: 
http:// dx .doi .org/ 10 .1371/ journal .pone .0205166 PMID: 30325963
38. Tsuji K, Tsutani K. Approval of new drugs 1999-2007: comparison of the US, 
the EU and Japan situations. J Clin Pharm Ther. 2010 Jun;35(3):289–301. doi: 
http:// dx .doi .org/ 10 .1111/ j .1365 -2710 .2009 .01099 .x PMID: 20848767
39. National Action Plan on Antimicrobial Resistance (AMR) 2016–2020. Tokyo: 
Government of Japan; 2016. Available from: https:// www .mhlw .go .jp/ file/ 
06 -Seisakujouhou -10900000 -Kenkoukyoku/ 0000138942 .pdf [cited 2019 
Oct 4]. 
40. ECDC, EFSA Panel on Biological Hazards (BIOHAZ); EMA Committee for 
Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA Joint 
Scientific Opinion on a list of outcome indicators as regards surveillance 
of antimicrobial resistance and antimicrobial consumption in humans and 
food-producing animals. EFSA J. 2017 10 26;15(10):e05017. PMID: 32625307
41. Patel S, Jhass A, Hopkins S, Shallcross L. Informing the development of 
a standardised approach to measure antibiotic use in secondary care: a 
systematic review protocol. BMJ Open. 2019 May 14;9(5):e026792. doi: 
http:// dx .doi .org/ 10 .1136/ bmjopen -2018 -026792 PMID: 31092658
